TD Securities maintained a Buy rating on Valeant Pharmaceuticals (NYSE: VRX) with a price target of $260. Analyst Howard Schiller ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst EPS View

BTIG Thinks Valeant (VRX) Should Just Severe Ties with Philidor; PT Cut to $175October 26, 2015 2:53 PM Valeant Pharma (VRX) practices 'sounds illegal' - Citron's LeftOctober 26, 2015 12:12 PM Valeant (VRX) Answered Its Questions Well, But Other Questions Remain - Deutsche Bank October 26, 2015 11:15 AM Mizuho Provides Quick Thoughts on Valeant (VRX) Slides/CallOctober 26, 2015 9:14 AM Valeant Pharma (VRX) Files Presentation on Philidor; Says No Evidence of Illegal Activity To-DateOctober 26, 2015 7:28 AM Valeant Pharma (VRX) Releases Slides Ahead of Investor Conference CallOctober 26, 2015 7:28 AM